An HIV-infected cell culture was treated with the specific HIV proteinase inhibitor Ro 31-8959 for three months to analyse the antiviral effect and possible cytotOXicity of the drug in long-term treatment. The drug was added 1 h after HIV infection with 0.002 m.o.i. and maintained for 87 days in the cell culture. There was no detectable cell death nor any evidence of HIV production in this time. Cells were proven to be initially infected, since premature drug removal led to a re-emergence of infectious HIV and cell death. However, after 87 days of treatment the drug could be removed safely and HIV was cleared demonstrably from the culture. These data suggest that long-term dosage may be advantageous to the clinical treatment of HIV infection by HIV proteinase inhibitors.
Introduction
Retroviral-encoded aspartic proteinases, such as the HIV-encoded proteinase, process precursors of viral structural and enzyme proteins necessary to yield matured, infectious viruses. The proteinase is hence an . attractive target for antiviral therapy (for a review, see Debouck, 1992) . Compounds, mainly peptidomimetics, specifically designed to inhibit the HIV proteinase have exhibited powerful antiviral effects (Erickson et al., 1990; McQuade et sl., 1990; Meek et al.,1990; Roberts et al., 1990; Vacca et al., 1991) .
In short-term (3-20 days) experiments in cell cultures, substances such as Ro 31-8959 (Roberts et al.,1990) blocked the viral proteinase activity, resulting in the formation of immature, non-infectious HIV particles unable to productively infect permissive cells (Ashorn et al., Received 4 October, 1993; revised 26 November, 1993; accepted 12 January, 1994. -ror correspondence. Tel. 089 5160 5257; Fax 089 538 0584. 1990; Craig et al., 1991; Schatzl et al., 1991; Craig et al., 1992; Lambert et al., 1992) . This posed the question as to whether this block could be sufficient to save a cell culture infected with HIV from eventual extinction due to viral cytotoxicity by preventing the spread of infectious virus and thus allowing non-infected cells to outgrow the infected ones. In comparable experiments, treatment with HIV RT (reverse transcriptase) inhibitors for several weeks resulted in the elimination of virus from cell cultures (Vasudevachari et si., 1992; Dueweke et ei., 1993) .
In long-term experiments carried out over a period of 3-4 months, we determined how long the specific HIV proteinase inhibitor Ro 31-8959 (Roberts et al., 1990) , added immediately after HIV infection, has to be kept in the culture to overcome irreversibly HIV-induced cell destruction, i.e, to 'cure' HIV-infected cells in culture. The consequence of inhibitor removal during the inhibition period before the eventual 'cure point' was also studied.
Results
In preliminary experiments, cell lines such as Jurkat, H9, C8166, and PHA (phytohemaglutinin-A) -stimulated peripheral blood lymphocytes (PBL) were infected with HIV-1 (III B) and treated for up to 7 weeks with the inhibitor Ro 31-8959, but no clear-cut results for a termination point of the inhibitor treatment could be obtained. In the series of 3-month-long inhibitor treatment experiments described here we used MT-4 cells because they respond reproducibly to HIV infection by cell death (Pauwels et al., 1987) , thus providing a convenient system for monitoring the antiviral, cell-protective effects of proteinase inhibitors.
Cells were infected and then separated into two aliquots: an untreated control culture and another to which the inhibitor Ro 31-8959 was added at a concentration of 100 nM 1h after infection and maintained in the culture (with daily replenishment) during the entire 3-month incubation period. In a series of earlier, comparable experiments in MT-4 cells we found that a concentration of 100 nM inhibitor was essential for reproducible, complete blocking of HIV cytotoxicity. Aliquots were taken from this inhibitor-treated culture at days 11, 42 and 87 post-incubation (p.l.), the inhibitor was removed and incubation was continued in the absence of inhibitor. For all aliquots, at various times, the following parameters were measured:
(i) the yield of released virus particles (determined as gag p24/p55); (ii) RT activity; (iii) the infectivity of the virus progeny produced (by reinfection assay in H9 cells); (iv) the amount of HIV proviral DNA in host cells (by peR), and (v) the ratio of infected/un infected cells within the culture population (determined by in situ immunostaining).
All resulting data are aligned in Fig.1 on the common time-scale of 120 days p.i. The set of experiments described here in detail was performed with an m.o.i. (multiplicity of infection) of 0.002 to mimic closely the physiological situation of infection by HIV in the peripheral blood system, where only about 1 in 10000-100000 peripheral cells are initially infected (Ou et al., 1988) ; higher local concentrations of HIV may occur in lymphoid or dendritic cells, as recently reported (Embretson et al., 1993; Pantaleo et al., 1993) . From our experiments we later concluded that less than 1 in 10000 MT-4 cells were productively infected at the outset.
Control infection without inhibitor
MT-4 cells were infected but no inhibitor was added. Despite the low m.o.i., after only three days p,l. PCR became positive and HIV particles were released from the cell culture, being detected as HIV gag p24/p55 in the cell culture supernatant, RT activity from pelleted, i.e. particlecontaining supernatant, and positive infectious virus titre ( Fig.1 , open circles, shows data for p24, RT activity and infectious virus titre at day 3 p.i.), Virus production then increased logarithmically and spread over the cell culture until the entire (100 %) host population was infected. By day 6 p.L (according to a trypan blue exclusion assay; Fig. 1 , lower section) or even before (according to 3H-thymidine incorporation; Fig. 1 , upper section), the cytotoxic effect of HIV affected host cells so severely that already 40 % of the population was destroyed. More than 90 % of the cells were destroyed after days 11-14 p.i, ( Fig.2a ) and the culture was entirely extinguished by day 32 p.i.,
Infection plus addition of inhibitor
The course of HIV infection in MT-4 cells treated with 100 nM of inhibitor Ro 31-8959, added 1 h after infection and kept in the culture with daily renewals, differed entirely from that of the control. There was no detectable cell death nor any evidence of HIV production (non-infectious or infectious particles) in the 4-month period of the experiment ( Fig.1, filled circles, for all data). Correspondingly, no intracellular viral antigen expression measured by in situ immunostaining of the cells was detectable. No signs of drug toxicity were detected throughout the period of treatment ( Fig. 2b ). Also, PCR was negative at all times. EVidence for an initially existent but PCR-undetectable amount of infected cells in the inhibitor-treated culture came from the experiments in which, upon inhibitor removal and further incubation, PCR turned positive. These cells began gradually to exhibit all signs of productive infection, unexplainable without an initially successful HIV infection and the presence of HIV provirus.
Removal of inhibitor
Removal of the inhibitor from an aliquot of infected MT-4 cells at day 11 p.l. and continuation of incubation without the inhibitor but with otherwise identical culture conditions resulted in syncytia formation 6 days after inhibitor removal. Ten days after removal of the inhibitor (= 21 days p.i.) a rapid increase in cell death occurred (Fig.1, bottom section, filled squares), comparable in slope and pattern to that of the uninhibited control (Fig.1, bottom section, open circles), leading to the death of the entire culture about 34 days after the removal of the inhibitor (= 45 days p.l.), Removal of the inhibitor from an aliquot of infected and inhibitor-treated cells at day 42 p.i, resulted in a pattern different from this. Although a clear decline in the viability of cells (about 30 %) was observed within the 2 weeks following inhibitor removal (l.e, 56 days p.i.), the cells later recovered but nevertheless produced infectious virus ( Fig.1, open squares) . The virus progeny of these 'chronically' infected cells was not mutated, as revealed by RT-PCR of the viral RNA or cDNA and consecutive sequencing of the proteinase region (data not shown).
However, when the inhibitor was removed from the HIV-infected MT-4 cells after a much longer time (i.e. 87 days p.l.) and the cells were thereafter maintained in culture for up to 1 month, no indication of viral replication or expression, or of any remaining HIV cDNA sequence, was found, by p24 protein EIA, by RT activity testing or by PCR screening. Consequently no cell death was observed. These cells have since been frozen and recultivated several times without exhibiting any signs of HIV infection such as the detection of HIV p24, RT activity or proviral DNA. In summary, the cells are by all tests free of HIV.
This experiment is representative of three replicate experiments at 100 nM inhibitor concentration.
Discussion
The results of our long-term experiments treating HIVinfected MT-4 cells with the highly specific HIV-PR inhibitor Ro 31-8959 allow four major conclusions.
(1) In the presence of 100 nM inhibitor, virus is either not released from the initially infected cells or is released in an undetectable amount and is non-infectious. Within the period of potential infectivity (at least up to day 42 p.i.), the presence of inhibitor reliably prevented not only the release of infectious virus but apparently also a conceivable cell-to-cell (syncytial)-mediated viral spread.
After 3 months of continuous inhibitor treatment, the infected culture was 'cured' completely of HIV infection. The initially infected cells eventuall¥lied, obviously as a result of HIV cytopathogenicity. CoHtinued incubation of cells for 33 more days beyond inhibitor removal at day 87 . p.l, yielded no evidence of remaining HIV infection (neither p24 nor RT activity nor PCR of HIV proviral sequences). The 'clearance' of infected cells takes place between days 42 and 87 p.i., as removal of inhibitor at 42 days p.l. still leads to a re-emergence of infection.
Half of the cell culture was discarded every 2 weeks to balance cell overgrowth; hence it could be argued that the infected cells are finally diluted out. However, as HIV integrates its proviral DNA eventually into the host genome, the progeny cell population inherits infectious HIV and cell dilution just balances cell overgrowth, and infectious cells are unlikely to be completely diluted out.
The inhibitor concentration of 100 nM necessary for full efficiency seems high in relation to the published IC50 and IC90 data in the ranges 1-10 and 5-50 nM, depending on cell type and virus isolate (Craig et al.,1991) . However, (i) MT-4 cells have the highest IC50 (about 12 nM) of the tested cells (H. Nitschko et el., Max-von-Pattenkofer Institut, unpublished; Mous et al., Roche-Basel, personal communication) and (ii) we had empirically determined in prior experiments that the concentration of 100 nM is necessary, because with less than 100nM a 'leakiness' (of protection against infecting virus) occurred after 1-2 months, resulting eventually in a pattern of cell death comparable to an early removal of the inhibitor.
(2) On early removal of the inhibitor from the culture (I.e. at day 11 p.i.), production of infectious virus is initiated and proceeds at an increasing rate, spreading within 10 days over the entire culture and resulting eventually in total cell death. This occurs with a comparable pattern Ro 31-8959 cures HIV infection in long-term cultures 239 and rate of reduction of cell viability (Fig. 1, closed  squares) as for the untreated control (open circles).
(3) Inhibitor removal at an intermediate stage during the 3-month inhibition experiment (in our studies at day 42 p.i.) yielded different results. Infectious HIV was released in increasing amounts and cells began to die. After 2-3 weeks, however, cell death ended and cells began to tolerate the cytotoxic effect of HIV and eventually appeared to be 'resistant' to cell destruction. Infectious virus was still released but no longer destroyed the host cells. In reinfection assays in fresh MT-4 cells, however, this virus killed the newly infected cells at the same rate as does 'normal' cytotoxic virus released from freshly infected cells. When the 'tolerant' cells were superinfected with fresh virus they were not destroyed. Both results indicate a resistance to viral cytotoxicity at the cellular level.
(4) A selection of drug-resistant virus was unlikely in our studies because of the experimental design, l.e, a very low infectious dose and non-increasing inhibitor concentrations throughout the long-term experiment. Nevertheless, we tested for mutations at the target by nucleotide sequencing, but did not find any mutation within the proteinase region in any of the virus progeny produced, l.e, no classical type of resistance had occurred at the antiviral target.
Similar long-term experiments with other infected lymphoblastic cells, such as H9, Jurkat, C 8166 and PHAstimulated PBL, are in progress. With PBL the technical problem of maintaining cell viability has so far prevented culture beyond 3 weeks.
In comparable experiments that used RT inhibitors, but a different experimental design for the HIV-infected cell culture, l.e. mixing of uninfected cells with the infected ones, it was reported that the drug could be removed from virus-free cells after 15-25 days p.i. (Vasudevachari et al., 1992 , Dueweke etal., 1993 .
Taken together, our results demonstrate that, at least within the test system described, long-term continued treatment of an HIV-infected cell culture with 100 nM (a relatively high dose) of Ro 31-8959 leads to an apparent clearance of HIV from the culture with no sign of drug toxicity. However, premature removal or a sub-optimal concentration of the drug can lead to a re-emergence of infectious virus spread, and possibly at later times to a cellular tolerance of HIV-induced cytotoxicity. The latter phenomenon, although confirmed by us in other cell lines such as H9 and C 8166, is not fully understood (data to be published elsewhere).
The inhibitory substance Ro 31-8959 is presently undergoing clinical trials. The relevance of our observations to the clinical treatment of HIV infection by HIV proteinase inhibitors will clearly have to be defined by such clinical trials, and it has to be determined at which viral burden a conceivable control of HIV infection might be achieved.
Moreover, the data suggest that long-term dosage may be advantageous clinically if this is not compromised by drug toxicity or an emergence of drug-resistant virus within the patients.
Materials and Experimental procedures

Substances
The peptidomimetic proteinase inhibitor Ro 31-8959 (N-tertbutyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[-(2-quinolycarbonyl)-l-asparaginyl]amino]butyl]4aS,8aS)-isoquinoline-3(S)-carboxamine methansulfonate (Fig. 3) (micronized) was kindly provided by Roche Products Ltd, WelwynGarden City, UK. It was originally referred to as compound XVII (Roberts at a/., 1990) .
Cells and virus
The human immunodeficiency virus strain HIV-1 IIiB was kindly provided by Dr R.C. Gallo, Bethesda, USA. MT-4, Jurkat, H9, PHB stimulated PBl and C 8166 cells were grown in RPMI 1640 medium supplemented with 15 % fetal calf serum.
Infection was as follows: 6 x 10 7 MT-4 cells were infected for 1 h at 3YOC (with 0.002 m.o.i.); another aliquot of 3 x 10 7 noninfected MT-4 cells served as negative control for the PCRand 3H-thymidine uptake analysis. After 1 h of infection the cells were sedimented for 2 min at 200 g, the virus-containing supernatant was removed and the cells were resuspended in fresh medium. The cell concentration was adjusted to 1 x 10 6 MT-4 cells rnr' culture medium and the cell suspension was equally distributed into six culture flasks each containing 1 x 10 7 cells in a final volume of 10ml medium. 100J.l1 of the inhibitor Ro 31-8959 (10-5 M dissolved in 1:1 DMSO/RPMI 1640) was added to each of three flasks (final inhibitor concentration 1 x 10 -7 M). Three flasks were treated with 100 J.l 1 DMSO:RPMI 1:1 (without inhibitor) and served as positive controls.
To provide optimally constant cell growth conditions and to ensure a constant concentration of inhibitor, every day 80 % of the cell supernatant was replaced with fresh medium and inhibitor (in more recent experiments we found that a replacement every other day might also be sufficient.) Under our particular cell culture conditions, i.e. with a high cell density (10 6 cells ml-1 ) at infection, the population doubled only within 12-15 days; thus every other week 50 % of the cell population was discarded.
Determination of HIV-1 particle production
The amount of cell-released virus particles was determined using a commercially available p24 antigen capture assay (Abbott, Wiesbd., Germany) which also recognizes the p55 gag precursor, which is important in those infection stages where particle maturation (i.e. gag processing) was blocked by the inhibitor. The supernatants from infected cells were collected every 24 h and the medium was cleared of cell debris by two rounds of low-speed centrifugation (2 min, 200 g; 10 min, 1200 g). 400J.l1 of the virus-containing supernatant was incubated with 20J.l1 20% Triton X-100 for 20min at 37°C and an aliquot was tested in an appropriate dilution for the amount of p24/p55, according to the protocol of the manufacturer. To ensure that gag p24 testing from supernatant actually correlates with the amount of produced particles (and not only free p24) we tested in parallel RT activity from pelleted supernatant and also HIV infectiVity in the supernatant.
HIV-1 infectivity assay
The infectious virus titre was determined by incubation of H9 cells on microtitre plates with serially diluted cell-free culture supernatants harvested from infected MT-4 cells. The H9 cells were incubated for 4 days in RPMI 1640 medium without inhibitor. The culture medium was changed every day and the production of virus particles was determined 4 days p.i. by a p24 antigen capture assay as described above.
Reverse transcriptase activity
The virus particles were collected by centrifugation as described (schatz: at a/., 1991). The virus pellet was resuspended in 100 J.l 1 RT lysis buffer (50 mM Tris-HCI, pH 7.8, 0.5 % Triton X-100, 2.5mM DTT, 80mM KCl, 0.75mM EDTA) and assayed (Eberle and Seibl, 1992) in a commercially available (Boehringer, Mannheim) ELISA-based non-radioactive test for RT activity. Briefly, the newly synthesized DNA is doubly labelled with digoxigenin-dUTP and biotin-dUTP in a standard RT reaction which contains dTTP. The in vitro generated DNA is immobilized on streptavidin-coated microtitre plates and detected immunologically by binding of peroxidase-labelled anti-digoxigenin sheep antibodies followed by colour development with ABTS [2,2'-azino-di(3-ethylbenzthiazolin-sulfonate)] substrate.
[3]H-Thymidine incorporation
The rates of DNA synthesis of untreated and inhibitor-treated MT-4 cells and their ability to replicate were assayed by incubation of 1.4 x 10 6 MT-4 cells with 15 /lCi 3H-thymidine (88 Ci mrnor') for 1 h at 37°C (Wilson, 1986) . At the end of the incorporation period the labelled cells were pelleted (3 min, 1200 g) and washed twice with PBS. The cells were finally resuspended in 100 ul cell lysis buffer (Solution 1, Kontron, Neufahrn, Germany) and the labelled DNA was precipitated with 10% cold TCA in 0.01 M sodium phosphate onto DEAE 81 filters and washed with EtOH. The amount of TCA-precipitable 3H-thymidine was determined in a Kontron MR 300 liquid scintillation counter with the fixed 3H-window setting.
Determination of cell viability by dye exclusion assay
For trypan blue staining (Wilson, 1986) ir~.5 ml cell suspension was pelleted (2 min, 200 g) and the calf~were resuspended in 1.6 ml PBS. The cells were stained W~h 0.9 ml 0.5% (w/v) trypan blue in PBS for 4 min. The total number of cells and the percentage of dead (blue-stained) MT-4 cells were determined in a 'Neubauer' chamber.
Detection of viral antigen in infected cells by immunostaining
MT-4 cells were washed twice with protein-free 30 mM HEPESbuffered MEM, pH 7.4 (Eagle; Gibco, Paisley, UK). Multi-spot slides coated with poly-L-Iysine (Kranz and Thierfelder, 1986) were washed with PBS, and 10 ul of cell suspension containing 5 x 10 3 to 4 x 10 4 cells was added to each well and incubated for 30 min at 4 DC. Following removal of the medium, cells were fixed for 7 min with 0.05 % freshly prepared glutaraldehyde in PBS and permeabilized for 20 min with 0.04 % Brij 56 in PBS. Immune reactions were performed by addition of 10 /ll Of 1:6400 diluted polyclonal human anti-gag antiserum, followed by incubation with anti-lgG Pox conjugate for 30 min at room temperature and three washes with PBS. 3-amino-9-ethylcarbazole (AEC, Sigma, St Louis, MO) was applied for 25 min as substrate for the enzyme reaction. The cells were counterstained for 55 s with Mayers acid haemalum and sealed under coverslips with a mixture of 80% glycerol, 15% 0.1 M phosphate buffer pH7.4 and 5% glutaraldehyde (25%). The percentage of gag-positive MT-4 cells was determined with a Zeiss Axloskop microscope (Zeiss, Germany) (MC 100 camera).
Analysis of HIV-1 DNA by PCR and PCR-sequencing
The presence of HIV-1-specific DNA in infected cells was determined by polymerase chain reaction (PCR) (Saiki et al.,1988) using two oligonucleotides corresponding to the nucleotides 1683-1702 (CAGAGCAGACCAGAGCCAAC; 5' Ro 31-8959 cures HIV infection in long-term cultures 241 primer) and 2188-2170 (CGGTCCTTACCTACCGGG; 3' primer) of the HIV-1 genome encompassing the complete coding region for the viral proteinase. DNA from 1.4 x 10 6 MT-4 cells was extracted, precipitated with EtOH and finally dissolved in 10 /ll sterile water. PCR reactions were performed in a final volume of 40/l1 using different amounts of DNA corresponding to 0.001, 0.01, 0.05 and 1.0 /ll DNA suspension. Reaction conditions were: 94 DC 1,5 min, 60 DC 1 min, 72 DC 1,5 min, 40 cycles; 10 mM Tris pH 8.3, 50 mM KCI, 1,5 mM MgCI 2 , 250 uM for each dNTP, 1.5 U Taq-polymerase (Perkin-Elmer, Uberlingen, Germany) and 20 pmol of each primer. The PCR products were analysed by Souihern blotting using a PCR-prepared probe and restriction enzyme analysis to verify the correctness of the amplified DNA product. The sensitivity of the assay was about 1pg of HIV DNA. Sequencing (Sanger et al., 1977) of HIV cDNA PCR products was carried out with the Applied Biosystem (Weiterst, Germany) sequencer according to the manufacturer's protocol.
